Added to YB: 2023-12-27
Pitch date: 2023-12-26
VAXX [bearish]
Vaxxinity, Inc.
+99.31%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.
Market Cap
$25.3K
Pitch Price
$1.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.28
P/E
-0.00
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
Vaxxinity (VAXX) - When Your Biggest Corporate Asset is a Private Plane
VAXX: Biotech pivoted to chronic disease vax despite efficacy doubts. Founders lack acclaim but have biz/law expertise. No CFO, SVP tied to struggling biotechs. Pvt plane 2/3 of assets excl cash, 2.5x>lab equip. $50M burn vs $30M net cash implies dilution to fund founders' plane access til fail
Read full article (3 min)